Your browser doesn't support javascript.
loading
Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial.
Delforge, Michel; Otero, Paula Rodríguez; Shah, Nina; Moshkovich, Olga; Braverman, Julia; Dhanda, Devender S; Lanar, Sally; Devlen, Jennifer; Miera, Matthew; Gerould, Heather; Campbell, Timothy B; Munshi, Nikhil C.
Afiliação
  • Delforge M; University Hospital Leuven, Leuven, Belgium. Electronic address: michel.delforge@uzleuven.de.
  • Otero PR; Clínica Universidad de Navarra, Pamplona, Spain.
  • Shah N; UCSF Medical Center, San Francisco, CA, USA.
  • Moshkovich O; ICON plc, San Francisco, CA, USA.
  • Braverman J; Bristol Myers Squibb, Princeton, NJ, USA.
  • Dhanda DS; Bristol Myers Squibb, Princeton, NJ, USA.
  • Lanar S; ICON plc, Lyon, France.
  • Devlen J; ICON plc, Gaithersburg, MD, USA.
  • Miera M; ICON plc, Gaithersburg, MD, USA.
  • Gerould H; ICON plc, Gaithersburg, MD, USA.
  • Campbell TB; Bristol Myers Squibb, Princeton, NJ, USA.
  • Munshi NC; Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, and Boston VA Healthcare System, Harvard Medical School, Boston, MA, USA.
Leuk Res ; 129: 107074, 2023 06.
Article em En | MEDLINE | ID: mdl-37087950
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias de Plasmócitos / Receptores de Antígenos Quiméricos / Mieloma Múltiplo Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias de Plasmócitos / Receptores de Antígenos Quiméricos / Mieloma Múltiplo Idioma: En Ano de publicação: 2023 Tipo de documento: Article